JP7311489B2 - 異種ｒｅｐＲＮＡ免疫化のための方法および組成物 - Google Patents

異種ｒｅｐＲＮＡ免疫化のための方法および組成物 Download PDF

Info

Publication number
JP7311489B2
JP7311489B2 JP2020504146A JP2020504146A JP7311489B2 JP 7311489 B2 JP7311489 B2 JP 7311489B2 JP 2020504146 A JP2020504146 A JP 2020504146A JP 2020504146 A JP2020504146 A JP 2020504146A JP 7311489 B2 JP7311489 B2 JP 7311489B2
Authority
JP
Japan
Prior art keywords
composition
reprna
ivt
antigenic
immune response
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020504146A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528911A (ja
JP2020528911A5 (enExample
Inventor
ヴォゲルス，ロナルド
デル ヌー コルフショーテン，マライン ヴァン
ジェィ． アーヴァイン，ダレル
ウェイス，ロン
ブラントン ポーター，イーリー
バンデイラ メロ，マリアンヌ
キタダ，タスク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Vaccines and Prevention BV
Original Assignee
Janssen Vaccines and Prevention BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines and Prevention BV filed Critical Janssen Vaccines and Prevention BV
Publication of JP2020528911A publication Critical patent/JP2020528911A/ja
Publication of JP2020528911A5 publication Critical patent/JP2020528911A5/ja
Application granted granted Critical
Publication of JP7311489B2 publication Critical patent/JP7311489B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/36011—Togaviridae
    • C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
    • C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
JP2020504146A 2017-07-28 2018-07-27 異種ｒｅｐＲＮＡ免疫化のための方法および組成物 Active JP7311489B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201762538070P 2017-07-28 2017-07-28
US62/538,070 2017-07-28
US201762546259P 2017-08-16 2017-08-16
US62/546,259 2017-08-16
PCT/US2018/044075 WO2019023566A1 (en) 2017-07-28 2018-07-27 METHODS AND COMPOSITIONS FOR PROVIDING IMMUNIZATION AGAINST Heterologous ARNREP

Publications (3)

Publication Number Publication Date
JP2020528911A JP2020528911A (ja) 2020-10-01
JP2020528911A5 JP2020528911A5 (enExample) 2021-08-26
JP7311489B2 true JP7311489B2 (ja) 2023-07-19

Family

ID=63407511

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020504146A Active JP7311489B2 (ja) 2017-07-28 2018-07-27 異種ｒｅｐＲＮＡ免疫化のための方法および組成物

Country Status (12)

Country Link
US (2) US11235051B2 (enExample)
EP (1) EP3658179B1 (enExample)
JP (1) JP7311489B2 (enExample)
KR (1) KR102806640B1 (enExample)
CN (1) CN111163799A (enExample)
AU (1) AU2018306614B2 (enExample)
BR (1) BR112020001052A2 (enExample)
CA (1) CA3071011A1 (enExample)
IL (1) IL272281B2 (enExample)
MA (1) MA49693A (enExample)
SG (1) SG11202000019RA (enExample)
WO (1) WO2019023566A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2021006925A (es) * 2018-12-14 2021-07-07 Glaxosmithkline Biologicals Sa Composiciones y metodos heterologos de vacunacion con refuerzo inductor.
TWI852977B (zh) 2019-01-10 2024-08-21 美商健生生物科技公司 前列腺新抗原及其用途
US11026894B2 (en) 2019-01-10 2021-06-08 Massachusetts Institute Of Technology Lipid nanoparticles and use thereof to deliver RNA polynucleotides
PH12022551208A1 (en) 2019-11-18 2023-04-24 Janssen Biotech Inc Vaccines based on mutant calr and jak2 and their uses
US11759515B2 (en) 2020-03-09 2023-09-19 Arcturus Therapeutics, Inc. Compositions and methods for inducing immune responses
WO2022009052A2 (en) 2020-07-06 2022-01-13 Janssen Biotech, Inc. Prostate neoantigens and their uses
WO2022036170A1 (en) 2020-08-14 2022-02-17 Arcturus Therapeutics, Inc. Method of lyophilizing lipid nanoparticles
AU2022224967A1 (en) 2021-02-23 2023-07-27 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutation
AR125191A1 (es) 2021-03-22 2023-06-21 Lifeedit Therapeutics Inc Enzimas modificadoras del adn y sus fragmentos activos y variantes y métodos de uso
CN115232824B (zh) * 2021-04-22 2023-09-26 中国人民解放军军事科学院军事医学研究院 一种基于1083骨架的预防狂犬病毒感染的疫苗
CN118119714A (zh) * 2021-09-02 2024-05-31 瑞普利科特生物科学公司 具有异源非结构蛋白的经修饰的甲病毒
WO2023156505A1 (en) 2022-02-17 2023-08-24 Janssen Vaccines & Prevention B.V. Trimer stabilizing hiv envelope protein mutations r304v, n302m and t320l
CN116064597B (zh) * 2023-01-17 2024-04-26 北京大学 通过自主复制rna实现哺乳动物细胞中的定向进化和达尔文适应

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046621A2 (en) 2003-11-12 2005-05-26 The United States Of America As Represented By The Secretary Of The Navy Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
US20140271714A1 (en) 2013-03-15 2014-09-18 Monika Simmons Induction of an immune response against dengue virus using the prime-boost approach

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998010087A1 (en) 1996-09-06 1998-03-12 Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
US7285265B2 (en) 2002-04-25 2007-10-23 Crucell Holland B.V. Stable adenoviral vectors and methods for propagation thereof
ATE447037T1 (de) 2002-04-25 2009-11-15 Crucell Holland Bv Mittel und verfahren zur herstellung von adenovirusvektoren
DE602005017743D1 (de) 2004-01-23 2009-12-31 Angeletti P Ist Richerche Bio Impfstoffträger für schimpansen-adenovirus
US20100143302A1 (en) 2006-03-16 2010-06-10 Crucell Holland B.V. Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof
WO2008136845A2 (en) 2007-04-30 2008-11-13 Medtronic Minimed, Inc. Reservoir filling, bubble management, and infusion medium delivery systems and methods with same
WO2010085984A1 (en) 2009-02-02 2010-08-05 Okairos Ag Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof
KR101763093B1 (ko) 2009-02-02 2017-07-28 글락소스미스클라인 바이오로지칼즈 에스.에이. 시미안 아데노바이러스 핵산- 및 아미노산-서열, 이를 포함하는 벡터 및 이의 용도
US20110300205A1 (en) 2009-07-06 2011-12-08 Novartis Ag Self replicating rna molecules and uses thereof
EP4218799A1 (en) * 2009-07-15 2023-08-02 GlaxoSmithKline Biologicals S.A. Rsv f protein compositions and methods for making same
HRP20161352T1 (hr) * 2010-07-06 2016-12-02 Glaxosmithkline Biologicals Sa Čestice nalik na virione za unos samoreplicirajućih molekula rna
KR101879892B1 (ko) 2010-12-14 2018-08-17 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 아데노바이러스 혈청형 26 및 혈청형 35 필로바일러스 백신
EP3632463A1 (en) * 2011-04-08 2020-04-08 Immune Design Corp. Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responses
EP2729168A2 (en) 2011-07-06 2014-05-14 Novartis AG Immunogenic compositions and uses thereof
IN2014KN02929A (enExample) * 2012-07-06 2015-05-08 Novartis Ag
AU2015311868B2 (en) * 2014-09-03 2018-11-22 Bavarian Nordic A/S Methods and compositions for enhancing immune responses
WO2016187613A1 (en) * 2015-05-21 2016-11-24 Janssen Vaccines & Prevention B.V Methods and compositions for inducing protective immunity against filovirus infection and/or disease

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005046621A2 (en) 2003-11-12 2005-05-26 The United States Of America As Represented By The Secretary Of The Navy Enhancement of vaccine-induced immune responses and protection by heterologous boosting with alphavirus replicon vaccines
US20140271714A1 (en) 2013-03-15 2014-09-18 Monika Simmons Induction of an immune response against dengue virus using the prime-boost approach

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
INFECTION AND IMMUNITY, 2003, Vol. 71, No. 3, p.1491-1496
JOURNAL OF VIROLOGY, 2011, Vol.85, No.9, pp.4222-4233
Vaccine, 2008, Vol.26, pp.6108-6118

Also Published As

Publication number Publication date
US20200230225A1 (en) 2020-07-23
JP2020528911A (ja) 2020-10-01
US20220111033A1 (en) 2022-04-14
AU2018306614A1 (en) 2020-01-30
US11235051B2 (en) 2022-02-01
KR102806640B1 (ko) 2025-05-12
KR20200037818A (ko) 2020-04-09
BR112020001052A2 (pt) 2020-09-08
AU2018306614B2 (en) 2024-08-29
US11964007B2 (en) 2024-04-23
CN111163799A (zh) 2020-05-15
IL272281B (en) 2022-12-01
WO2019023566A1 (en) 2019-01-31
IL272281A (en) 2020-03-31
MA49693A (fr) 2020-06-03
IL272281B2 (en) 2023-04-01
EP3658179A1 (en) 2020-06-03
CA3071011A1 (en) 2019-01-31
EP3658179B1 (en) 2025-09-17
EP3658179C0 (en) 2025-09-17
SG11202000019RA (en) 2020-02-27

Similar Documents

Publication Publication Date Title
JP7311489B2 (ja) 異種ｒｅｐＲＮＡ免疫化のための方法および組成物
Mendonça et al. Adenoviral vector vaccine platforms in the SARS-CoV-2 pandemic
AU2003297039B2 (en) Multi-antigenic alphavirus replicon particles and methods
Capone et al. Development of chimpanzee adenoviruses as vaccine vectors: challenges and successes emerging from clinical trials
US20220062409A1 (en) Heterologous prime boost vaccine compositions and methods
US10561722B2 (en) Methods and compositions for enhancing immune responses
US11229692B2 (en) Methods and compositions for inducing protective immunity against RSV infection
AU2017297610A1 (en) Compositions and methods for alphavirus vaccination
Russell et al. Frontrunners in the race to develop a SARS-CoV-2 vaccine
Chang et al. Polyplex nanomicelle delivery of self-amplifying RNA vaccine
JP2020511145A (ja) 改良されたｌｉワクチンアジュバント
EA043316B1 (ru) СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ ГЕТЕРОЛОГИЧНЫХ репРНК ИММУНИЗАЦИЙ
EP4612305A1 (en) Binary self-amplifying nucleic acid platform and uses thereof
JP2022551107A (ja) アデノウイルスベクターおよびその使用
Matthews et al. 210. A Comparative Study of Non-Integrating and Integrating Lentiviral Vectors in Eliciting an Effective Immune Response Against Hepatitis B Surface Antigen in Mice

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210712

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210712

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220802

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221101

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230110

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230510

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230517

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20230620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230706

R150 Certificate of patent or registration of utility model

Ref document number: 7311489

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150